Unilever’s rejected £50bn bid for GSK health is ‘final offer’

UNILEVER has ruled out a fourth bid for the consumer healthcare business of drugs giant GSK, after its third offer of £50billion was knocked back. GSK said that the unsolicited bids for its consumer healthcare business, which is best known for its Panadol, Sensodyne and Nicorette brands, had “fundamentally undervalued” its prospects.
Daily Express :: City and Business Feed

LEAVE A REPLY

Please enter your comment!
Please enter your name here